Biotech Stocks Added this
Week; ($CLBS), ($DCTH), ($GEMP) ($RTTR)
Biotech, Mining,Tech,
Cannabis, Sports, Renewables, Energy and Entertainment Stocks added
Point Roberts, WA, Delta BC – June 2, 2017 –
Investorideas.com, a global news source and investor resource covering actively
traded sectors announces this week’s additions to its global stock directories
in Biotech, Tech, Sports, Renewables, Mining, Cannabis, Energy and
Entertainment.
Investorideas.com tracks companies in high profile
trading sectors and makes ongoing additions to its stock directories for each
sector. Listing for the stock directories include companies on the
TSX, OTC, NYSE, NASDAQ and global stock exchanges.
The newest biotech and life sciences companies are
involved in cancer treatments, treatments for addiction, autoimmune and
cardiology disease, cardiometabolic disorders, pain treatments and
gastrointestinal disease.
Also new this week is the IPO Assure Holdings Corp
(TSX:IOM.V) a Colorado based company, incorporated in the State of Nevada, that
works with neurosurgeons and orthopedic spine surgeons to provide a turnkey
suite of services that support intraoperative neuromonitoring activities during
invasive surgeries.
New Biotech Companies Added to Investorideas directory:
Assure Holdings Corp (TSX:IOM.V) is a Colorado based company, incorporated in the State of Nevada, that
works with neurosurgeons and orthopedic spine surgeons to provide a turnkey
suite of services that support intraoperative neuromonitoring activities during
invasive surgeries. Assure: (i) employs
its own staff of technologists and uses its own state of the art monitoring
equipment, (ii) handles 100% of intraoperative neuromonitoring scheduling and
setup, and (iii) bills for all technical services provided. While Assure focuses primarily on supporting
spinal surgeries, plans are in place to support other classes of medicine that
rely on the standard of care that intraoperative neuromonitoring provides.
BioCorRx (OTC: BICX) is an addiction treatment company offering a
unique approach to the treatment of substance abuse addiction. The BioCorRx®
Recovery Program, a non-addictive, medication-assisted treatment (MAT) program,
consists of two main components. The first component of the program consists of
an outpatient implant procedure performed by a licensed physician. The implant
delivers the non-addictive medicine, naltrexone, an opioid antagonist that can
significantly reduce physical cravings for alcohol and opioids. The second
component of the program developed by BioCorRx Inc. is a proprietary counseling
program (plus peer support program) specifically tailored for the treatment of
alcoholism and other substance abuse addictions for those receiving long-term
naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx
Pharmaceuticals, which is currently developing a new injectable naltrexone
technology (BICX101) through a partnership with TheraKine Ltd. The Company
plans to seek FDA approval for BICX101 and/or its naltrexone implant
product(s).
Caladrius
Biosciences, Inc. (NasdaqCM:CLBS) is a clinical stage development company with cell therapy products in
development based on multiple technology platforms and targeting autoimmune and
select cardiology indications. The Company is investigating its lead product
candidate, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for
the treatment of recent-onset type 1 diabetes in a currently enrolling Phase 2
trial.
Delcath
Systems (NasdaqCM:DCTH) is an interventional oncology Company focused on the treatment of
primary and metastatic liver cancers. Our investigational product—Melphalan
Hydrochloride for Injection for use with the Delcath Hepatic Delivery System
(Melphalan/HDS) —is designed to administer high-dose chemotherapy to the liver
while controlling systemic exposure and associated side effects. We have
commenced a global Phase 3 FOCUS clinical trial for Patients with Hepatic
Dominant Ocular Melanoma (OM) and plan to initiate a Registration trial for
intrahepatic cholangiocarcinoma (ICC) in the Fall of 2017. Melphalan/HDS has
not been approved by the U.S. Food & Drug Administration (FDA) for sale in
the U.S. In Europe, our system has been
commercially available since 2012 under the trade name Delcath Hepatic
CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at
major medical centers to treat a wide range of cancers of the liver.
Gemphire
Therapeutics Inc (NasdaqGM:GEMP) is a clinical-stage biopharmaceutical company that is committed to
helping patients with cardiometabolic disorders, including dyslipidemia and
NASH. The Company is focused on
providing new treatment options for cardiometabolic diseases through its
complementary, convenient, cost-effective product candidate gemcabene as add-on
to the standard of care especially statins that will benefit patients,
physicians, and payors. Gemphire has
initiated 3 clinical trials for homozygous familial hypercholesterolemia
(HoFH), heterozygous familial hypercholesterolemia (HeFH)/atherosclerotic
cardiovascular disease (ASCVD), and severe hypertriglyceridemia (SHTG) under
NCT02722408, NCT02634151, and NCT02944383, respectively with a fourth planned
trial in NASH to initiate in second half of 2017
PixarBio (OTC:PXRB) is a specialty
pharmaceutical/biotechnology company focused on pre-clinical and commercial
development of novel neurological drug delivery systems for post-operative
pain. PixarBio researches and develops targeted delivery systems for drugs,
cells, or biologics to treat pain, epilepsy, Parkinson’s disease, and spinal
cord injury. Our lead product platform, NeuroRelease™, has achieved sustained
therapeutic release of non-opiate drugs for post-operative, acute and chronic
pain in pre-clinical models.
Propanc
Health Group Corporation (OTC:PPCH) is a clinical stage biopharmaceutical company developing new cancer
treatments initially for patients suffering from pancreatic, ovarian and
colorectal cancers. We have developed a formulation of anti-cancer compounds,
which exert a number of effects designed to control or prevent tumors from
recurring and spreading throughout the body. Our products involve or employ
pancreatic proenzymes, which are inactive precursors of enzymes. In the near
term, we intend to target patients with limited remaining therapeutic options
for the treatment of solid tumors. In future, we intend to develop our lead
product to treat (i) early stage cancer and (ii) pre-cancerous diseases and
(iii) as a preventative measure for patients at risk of developing cancer based
on genetic screening.
Ritter Pharmaceuticals (NasdaqCM:RTTR) develops novel therapeutic products that modulate the gut microbiome
to treat gastrointestinal diseases. Its lead product candidate, RP-G28, has the
potential to become the first FDA-approved treatment for lactose intolerance, a
condition that affects millions worldwide. The company is further exploring the
functionality and discovering the therapeutic potential gut microbiome changes
may have on treating/preventing a variety of conditions including:
gastrointestinal diseases, immuno-oncology, metabolic, and liver disease.
BioCorRx (OTC: BICX) is an addiction treatment company offering a
unique approach to the treatment of substance abuse addiction. The BioCorRx®
Recovery Program, a non-addictive, medication-assisted treatment (MAT) program,
consists of two main components. The first component of the program consists of
an outpatient implant procedure performed by a licensed physician. The implant
delivers the non-addictive medicine, naltrexone, an opioid antagonist that can
significantly reduce physical cravings for alcohol and opioids. The second
component of the program developed by BioCorRx Inc. is a proprietary counseling
program (plus peer support program) specifically tailored for the treatment of
alcoholism and other substance abuse addictions for those receiving long-term
naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx
Pharmaceuticals, which is currently developing a new injectable naltrexone
technology (BICX101) through a partnership with TheraKine Ltd. The Company
plans to seek FDA approval for BICX101 and/or its naltrexone implant
product(s).
ICTV
Brands (OTC:ICTV) is a digitally focused, direct response marketing and branding company
focused on the health, wellness and beauty sector. The company has built a
scalable, multi-channel distribution strategy which enables it to acquire and
sell proprietary consumer products across traditional retail, e-commerce, live
home shopping, direct response television and direct to consumer digital
marketing campaigns and international distributor networks. The company has a
diverse and growing portfolio of products that have the potential for rapid
growth. ICTV Brands, Inc. was founded in 1998 and is headquartered in Wayne,
Pennsylvania.
InspireMD Inc. (NYSE MKT:
NSPR) seeks to utilize its proprietary MicroNet™
technology to make its products the industry standard for embolic protection
and to provide a superior solution to the key clinical issues of current
stenting in patients with a high risk of distal embolization, no reflow and
major adverse cardiac events. InspireMD intends to pursue applications of this
MicroNet technology in coronary, carotid (CGuard™), neurovascular, and
peripheral artery procedures.
Miramar
Labs (OTC:MRLB) is a global medical device company dedicated to bringing innovative
and clinically proven applications to treat unmet needs in the aesthetic
marketplace. Supported by rigorous clinical research, Miramar Labs is focused
on addressing aesthetic medical conditions for which there are significant
unmet clinical needs. The company’s first priority is the treatment of
bothersome underarm sweat, an issue that hundreds of millions of people deal with
daily. The miraDry procedure has an established safety and efficacy profile
with over 90,000 patients treated worldwide.
Investorideas.com global stock directories are part
of the membership program on the site, accessed either by login and password or
available in PDF format. The directories include stocks trading on the
TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving
retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/
The directories are not meant as recommendations
but as a research tool to discover opportunities and trading ideas in a
particular sector.
About
Investorideas.com - News that Inspires Big Ideas
www.Investorideas.com is a meeting place for global
investors, featuring news, stock directories, video, podcasts, company
profiles, interviews and more in leading sectors.
Sectors we cover include
tech, bitcoin and blockchain, biotech, mining, energy, renewable energy, water
stocks, marijuana and hemp stocks, food and beverage (including organic and
LOHAS, wine), defense and security (including biometrics), Latin America,
sports, entertainment, luxury brands and gaming.
The Investorideas.com
content portfolio goes beyond the www.investorideas.com site to include 12 blogs
on Blogger.com, 7 Artificial Intelligence (AI) websites on the Grid and
the Waternewswire.com, all featuring Investorideas.com news and content.
Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks,
renewable energy, nanotech, defense, technology, biotech and more – use our
stock directories and access them online 24/7 with login as a member to find
your next big idea!
Investorideas.com CSE service provider directory listing: http://thecse.com/en/services/services-for-listed-companies
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles. Original
content created by investorideas is protected by copyright laws other than
syndication rights. Our site does not make recommendations for purchases or
sale of stocks, services or products. Nothing on our sites should be construed
as an offer or solicitation to buy or sell products or securities. All
investment involves risk and possible loss of investment. This site is
currently compensated for news publication and distribution, social media and
marketing, content creation and more. Contact each company directly regarding
content and press release questions. Disclosure is posted for each compensated
news release, content published /created if required but otherwise the news was
not compensated for and was published for the sole interest of our readers and
followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Disclosure - Zinc One
(TSXV:Z)(OTC:ZZZOF) is a featured mining PR, news and social media client for
June 2017 – one month : five thousand per month via ad agency Disclosure - US Gold Corp
is a paid PR news distribution and social media client on
Investorideas.com effective June 1,2017 - two months : ten thousand per month
Additional info regarding BC Residents and global
Investors: Effective September 15 2008 - all BC investors should review all OTC
and Pink sheet listed companies for adherence in new disclosure filings and
filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to
regulations of each country.
Contact Investorideas.com
800-665-0411
No comments:
Post a Comment